On April 25, 2017 VBL Therapeutics (NASDAQ:VBLT), reported that new data on VB-111 will be presented at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2017 Annual Meeting, to be held June 2-6 in Chicago, Illinois, as well as in the 20th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper), to be held May 10-13 in Washington, DC (Press release, VBL Therapeutics, APR 25, 2017, View Source [SID1234518683]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from the Phase 2 clinical trial that investigated VB-111 in recurrent glioblastoma (rGBM) will be presented at ASCO (Free ASCO Whitepaper), as detailed below:

Title:

Treatment Through Progression with Ofranogene Obadenovec
(VB-111), an Anti-Cancer Viral Therapy, Significantly
Attenuates Tumor Growth in Recurrent GBM: Individual Phase
2 Patient Data
Abstract: 2055
Session Type: Poster Session
Session Title: Central Nervous System Tumors
Date: June 5, 2017
Time: 1:15 – 4:45 Central Time
Location: Hall A
Poster Board: #297
Presenter:

Andrew Jacob Brenner, MD, Ph.D., The University of Texas
Health Science Center at San Antonio, et al.
Previously announced data from this Phase 2 clinical trial showed prolongation of overall survival in rGBM patients treated with a combination of VB-111 and Avastin (bevacizumab) compared to limited exposure to VB-111 and to historical controls. This poster at ASCO (Free ASCO Whitepaper) will feature data on individual patients who were enrolled in this trial.

In addition, preclinical data demonstrating that VB-111 augments the anti-tumor activity of PD-L1 blockade will be presented at the ASGCT (Free ASGCT Whitepaper), as detailed below:

Title:

Vascular targeting viral therapy augments PD-L1 checkpoint
blockade anti-tumor activity
Session Date/Time: Friday, May 12, 2017 5:45 PM – 7:45 PM
Session title: Cancer-Immunotherapy, Cancer Vaccines III
Room: Exhibit Hall A & B South
Abstract number: 585
About Ofranergene Obadenovec (VB-111)
Ofranergene obadenovec is a unique biologic agent that uses a dual mechanism to target solid tumors. Based on a non-integrating, non-replicating, Adeno 5 vector, ofranergene obadenovec utilizes VBL’s proprietary Vascular Targeting System (VTS) to target the tumor vasculature for cancer therapy. Unlike anti-VEGF or TKIs, ofranergene obadenovec does not aim to block a specific pro-angiogenic pathway; instead, it uses an angiogenesis-specific sensor (VBL’s PPE-1-3x proprietary promoter) to specifically induce cell death in angiogenic endothelial cells in the tumor milieu. This mechanism retains activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor and shows activity even after failure of prior treatment with other anti-angiogenics. Moreover, ofranergene obadenovec induces specific anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells.

Ofranergene obadenovec completed a Phase 2 study in rGBM, which showed a statistically significant improvement in overall survival in patients treated with ofranergene obadenovec through progression, compared to either patients treated with ofranergene obadenovec followed by bevacizumab alone, or to historical bevacizumab data. In a Phase 2 trial for recurrent platinum-resistant ovarian cancer, ofranergene obadenovec demonstrated a statistically significant increase in overall survival and 60% durable response rate (as measured by reduction in CA-125), approximately twice the historical response with bevacizumab plus chemotherapy in ovarian cancer. In a Phase 2 study in recurrent, iodine-resistant differentiated thyroid cancer, ofranergene obadenovec met the primary endpoint demonstrating disease stabilization with a positive safety profile, along with a dose-response and evidence of an overall survival benefit. Ofranergene obadenovec has received Fast Track Designation for recurrent glioblastoma in the U.S. and orphan drug status for glioblastoma in both the U.S. and EU.